Mr. Stephen Van Deventer reports

PREVECEUTICAL SHOWCASES DYNAMIC EVOLUTION IN AI STRATEGY

Preveceutical Medical Inc. marks today as an important chapter in the journey of the company, a pioneering figure in the realm of medical technology. The company unveils a comprehensive narrative around its growing involvement and innovation in the vast domain of artificial intelligence (AI).

At the forefront of this initiative stands Shawn Sadler, the head of artificial intelligence. Mr. Sadler is not new to the intricacies of the tech landscape. With over 25 years of immersion in the IT industry, he embodies a reservoir of expertise that spans from AI frameworks and machine learning to data management and information governance. His appointment is strategic and expected to expedite Preveceutical's drive into leveraging AI to maximize the potential of its research data, improve workflow efficiencies and tap into predictive analytics.

Delving deeper into the infrastructure blueprint, the company is ardently sculpting a resilient platform on AWS SageMaker. Once fully operational, it is predicted to empower Preveceutical with the agility and scalability required for next-generation model development and data processing. Meanwhile, budding collaborations with industry giants like OpenAI promise to usher in avant-garde methodologies that could redefine the way the company approaches AI-driven research. Preliminary dialogues with HuggingFace are equally promising, potentially introducing sophisticated natural language processing tools to the platform.

Central to Preveceutical's AI strategy is its aspiration to harness vast repositories of specialized data, driving the next wave of medical insights and innovations. Acknowledging the indispensable value of targeted biomedical data recognition, Preveceutical is actively exploring avenues for integration with Bern2. Concurrently, the company will establish an API connection to NIH's National Center for Biotechnology Information, eyeing a future enriched by unparalleled biomedical and genomic data. The team is also mapping out plans to incorporate the Semantic Scholar API into its Large Language Model, confident in the expansive academic insights it can deliver.

Stephen Van Deventer, the chief executive officer of Preveceutical Medical, commented: "Today's AI narrative isn't just an update; it's a testament to our unwavering commitment to driving innovation. With leaders like Shawn helming our AI initiatives and the synergies we're aiming to develop with our potential collaborators, I am confident in Preveceutical's trajectory in the medical research landscape."

Mr. Van Deventer added: "The convergence of AI and medical research offers boundless possibilities. With our current momentum and the partnerships we're fostering, we're poised to not just navigate but shape the future of this exciting confluence."

About Preveceutical Medical Inc.

Preveceutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products. The company aims to be a leader in the preventive health sciences sector.

With the completion of three of its research programs, the company is actively working on the development, clinical trials and commercialization of its products, and has filed a number of provisional patent applications to protect the intellectual property from its research programs.

We seek Safe Harbor.